Live News Categoriesequity

Ascletis Pharma Inc. (1672.HK) News

Track canonical SquawkNews coverage tagged to 1672.HK, Ascletis Pharma Inc.. This hub brings together deduplicated headlines about hkse, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 1 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol 1672.HK Asset equity Sector Markets 90 days 1 Last 8.55 Updated Sep 29, 2026, 12:01 AM UTC Open live news feed

L Ascletis says ASC50 cuts PASI score 48.9% in 28-day U.S. psoriasis study The trial was a 28-day U.S. proof-of-concept study in plaque psoriasis. Ascletis said effects continued beyond the final dose and no serious events or liver-related signals were reported. EQUITY | Sep 29, 2026, 12:01 AM UTC